Cheyenne Buprenorphine Doctors


Feature Your Practice at the Top of This City Page

Locate Cheyenne buprenorphine and suboxone doctors who specialize in the treatment of opioid addiction.

Dr. Georgia Louise Young, D.O.
PO Box 1183
Cheyenne, WY 82003
Main Tel: (208) 304-5278
 
 
Dr. Julie B. Maggiolo, M.D.
Cheyenne Regional Medical Center
214 East 23rd Street
Cheyenne, WY 82001
Main Tel: (307) 633-7370
 
 
Dr. Eugene Leonard Roberts, Jr., M.D.
Cheyenne Regional Medical Center
214 East 23rd Street
Cheyenne, WY 82001
Main Tel: (704) 965-2002
 
 
Dr. Georgia Louise Young, D.O.
2909 Bent St.
Suite B2
Cheyenne, WY 82001
Main Tel: (307) 772-1836
 
 
Dr. James G. Haller, M.D.
123 Cole Shopping Center
Cheyenne, WY 82001
Main Tel: (307) 634-8802
 
 
Dr. Douglas W. Edgren, M.D.
1331 Prairie Avenue
Cheyenne, WY 82009
Main Tel: (307) 632-0728
 
 
Dr. Tharenie Sivarajah, M.D.
201 Walterscheid Boulevard
Apt 5-206
Cheyenne, WY 82007
Main Tel: (307) 274-5560
 
 
Jonathan Benaknin, D.O.
Behavioral Health Services
2600 East 18th Street
Cheyenne, WY 82001
Main Tel: (307) 634-2273
 
 
Jasper James Chen, M.D.
Cheyenne Regional Medical Center
2600 East 18th Street, Behavioral Health
Cheyenne, WY 82001
Main Tel: 603-650-5000
 
 
Dr. Lopa Bakul Zaveri, M.D.
Cheyenne Health and Wellness Center
2508 East Fox Farm Road
Cheyenne, WY 82007
Main Tel: (307) 635-3618
 
 

Sublocade Now Available

Sublocade is a newly released medication alternative for treating opioid addiction. It is a product of Indivior, the pharmaceutical company responsible for Suboxone. Sublocade is a once monthly injection of time-released buprenorphine typically provided to patients who have been receiving buprenorphine for at least (7) days and who are stable on their medication. The injection Read More

Posted in Buprenorphine, Medication-Assisted Treatment | Tagged | Leave a comment

Ohio Increases Buprenorphine Access

In 2017, Ohio increased its number of buprenorphine-approved prescribers by 266. This was the result of a $2.3 million dollar Federal grant that provided state-wide training to doctors, nurse practitioners, and physician assistants as reported by Cleveland.com. Historically, Ohio had numerous communities that were underserved with 19 counties having no buprenorphine providers at the beginning Read More

Posted in Addiction Medications, Buprenorphine, Medication-Assisted Treatment, Suboxone | Tagged , | Leave a comment

The Drug Treatment Act of 2000 permitted doctors who meet certain training qualifications to prescribe buprenorphine in the treatment of heroin addiction and other opioid addictions. Buprenorphine physicians became able to assist opioid addicted patients in an office setting bypassing the restrictions that typically apply to patients receiving methadone. This treatment method maximized patient convenience and accessibility thus increasing the number of people who could access medication-assisted treatment (MAT) for opioid addiction.

Buprenorphine is the medication ingredient in Suboxone, Subutex, Zubsolv, Bunavail, and Probuphine that specifically targets opioid withdrawal. Buprenorphine, or "Bup", is the leading pharmaceutical treatment (alongside methadone) for addressing opioid addiction. Both medications are in widescale use throughout the world due to their efficacy in removing the persistent discomfort associated with withdrawal from opiates (ex. runny nose, body ache, anxiety, nausea, diarrhea and other symptoms).

Buprenorphine.US is an information resource for people in search of doctors who specialize in treating opioid addiction with buprenorphine. In recent years, individuals from all age groups and backgrounds have suffered with an unexpected opioid dependency that negatively affected their family relationships, job, finances, and self-esteem. Addiction is a relentless illness, and persistent opiate withdrawal is a particularly difficult medical dilemma. There are presently thousands of U.S. physicians seeking to assist patients ready to address their opioid addiction. Buprenorphine.US is a tool for connecting buprenorphine doctors with new prospective patients wanting specialized primary care for their addictive disorder.